

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10568367
	Filing Date		2006-08-18
	First Named Inventor	Carlos GARCIA-ECHEVERRIA	
	Art Unit	1624	
	Examiner Name	2344	
	Attorney Docket Number	PAT032910B-US-PCT	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5958935		1999-09-28	Davis et al.	
	2	6093716		2000-07-25	Davis et al.	
	3	6114333		2000-09-05	Davis et al.	
	4	6048866		2000-04-11	Hutchings et al.	
	5	7671063		2010-03-02	Baenteli et al.	
	6	7514446		2009-04-07	Davis-Ward et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10568367
Filing Date		2006-08-18
First Named Inventor	Carlos GARCIA-ECHEVERRIA	
Art Unit	1624	
Examiner Name	2344	
Attorney Docket Number	PAT032910B-US-PCT	

	1	20060100227	A1	2006-05-11	Baenteli et al.	
	2	20060247241	A1	2006-11-02	Garcia-Echeverria et al.	
	3					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2004056786	WO	A1	2004-07-08	Pfizer Products Inc.		<input type="checkbox"/>
	2	2006068770	WO	A1	2006-06-29	Rigel Pharmaceuticals, Inc.		<input type="checkbox"/>
	3	2002056888	WO	A2	2002-07-25	Novartis AG		<input type="checkbox"/>
	4	1998041512	WO	A1	1998-09-24	Celltech Therapeutics Limited		<input type="checkbox"/>
	5	2001025220	WO	A1	2001-04-12	Kinetix Pharmaceuticals Inc.		<input type="checkbox"/>
	6	2005026130	WO	A1	2005-03-24	Novartis AG		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10568367
Filing Date		2006-08-18
First Named Inventor	Carlos GARCIA-ECHEVERRIA	
Art Unit	1624	
Examiner Name	2344	
Attorney Docket Number	PAT032910B-US-PCT	

	7	2005016894	WO	A1	2005-02-24	Novartis AG		<input type="checkbox"/>
--	---	------------	----	----	------------	-------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	TRAXLER, Peter M. , "Protein Tyrosine Kinase Inhibitors in Cancer Treatment", Expert Opinion on Therapeutic Patents, Vol. 7, No. 6, pp. 571-588, 1997.	<input type="checkbox"/>
	2	SIMONE et al., Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, Vol. 1, pp. 1004-1010, 1997.	<input type="checkbox"/>
	3	BASFORD et al., CAPLUS Abstract 41:763, pp. 7810-7812,1947.	<input type="checkbox"/>
	4	COOPMAN et al., "The Syk Tyrosine Kinase Suppresses Malignant Growth of Human Breast Cancer Cells", Nature, Vol. 406, pp. 742-747, August 17, 2000.	<input type="checkbox"/>
	5	USPTO Final Office Action mailed May 20, 2010, of pending U.S. Patent Application No. 10/549,250 (U.S. Patent Publication No. 2006/0247241).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.